MTOR and central nervous system cancer: Akt inhibits the target of mammalian target of rapamycin (mTOR) in gliomas, which regulates a variety of cellular responses, such as cytoskeletal structure, transcription, and autophagy, to enhance cell viability (Revathidevi and Munirajan 2019).